Fort Scott

Researchers are collecting and storing tissue and blood samples from patients with various types of cancer to help create better models for studying cancer and testing new cancer drugs. This observational study focuses on patients with hematopoietic and lymphatic system neoplasms, malignant solid tumors, metastatic malignant solid tumors, and recurrent malignant solid tumors. The goal is to procure biological tissues and materials to develop preclinical cancer models for future laboratory analysis. During the study, tumor tissue and blood samples are collected during medical procedures required for the patients cancer treatment. These samples are then preserved using methods such as xenograft models, where tissues are transplanted to another species, or in vitro cell cultures. This process allows for future scientific study without additional invasive procedures beyond routine clinical care. Participants will be involved in routine clinical procedures during which tissue and blood samples are collected. Researchers will store these specimens and monitor their use in creating cancer models over a period of up to five years. The main outcome measured is the successful procurement and storage of tissue and blood specimens for research purposes. Participation will continue as long as samples can be collected during clinical management, with no additional treatment or interventions required specifically for this study.

Researchers are evaluating several drugs to treat patients with progressive meningiomas, a type of brain tumor that is growing, spreading, or worsening. This phase II trial focuses on how four different inhibitorsvismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclibwork in patients whose tumors have specific genetic mutations affecting cell growth pathways. The goal is to measure progression-free survival and response rates over six months to better understand their activity against these tumors. Participants are assigned to treatment groups based on their tumors mutation status. Patients with SMO or PTCH1 mutations receive vismodegib daily those with NF2 mutations get FAK inhibitor GSK2256098 twice daily patients with AKT1, PIK3CA, or PTEN mutations take capivasertib twice daily for four days each week in a 28-day cycle and those with CDK pathway alterations receive abemaciclib every 12 hours. Treatments continue in 28-day cycles until disease progression or unacceptable side effects occur. After treatment ends, participants are followed up every six months for up to five years. Throughout the study, participants undergo regular assessments, including imaging scans reviewed centrally to evaluate tumor response, as well as monitoring for adverse events. Researchers track overall survival, progression-free survival, and side effects to understand the drugs activity and safety. The study involves close monitoring of laboratory tests, heart function, and medication interactions to ensure participant safety during treatment and follow-up.